The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei Avidity Biosciences, Inc. listata cu simbolul US.RNA ==Descriere companie== Avidity Biosciences, Inc. (http://www.aviditybiosciences.com/) is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therap...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Avidity Biosciences, Inc. (http://www.aviditybiosciences.com/) is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies. The Oligonucleotide therapeutics are designed based on genomic information to specifically inhibit or modify the expression of disease-related proteins and ribonucleic acids (RNA). It is focused on muscle diseases and consists of approximately five programs. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type one (DM1). It also focuses on other muscle programs focused on the treatment of facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy, muscle atrophy and Pompe disease. | Avidity Biosciences, Inc. (http://www.aviditybiosciences.com/) is a biopharmaceutical company. The Company focuses on oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC), designed to overcome the limitations of oligonucleotide-based therapies to treat a range of serious diseases. It utilizes its AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide-based therapies. The Oligonucleotide therapeutics are designed based on genomic information to specifically inhibit or modify the expression of disease-related proteins and ribonucleic acids (RNA). It is focused on muscle diseases and consists of approximately five programs. Its lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type [[one]] (DM1). It also focuses on other muscle programs focused on the treatment of facioscapulohumeral muscular dystrophy (FSHD), Duchenne muscular dystrophy, muscle atrophy and Pompe disease. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||